Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

June 13, 2016June 13, 2016

Solithromycin for Community Acquired Pneumonia Shows Positive Phase 2 Results

News, Pneumonia

Data from a Phase 2 clincial trial for solithromycin, a next-generation oral and intravenous fluoroketolide for the treatment of moderate to moderately-severe community acquired bacterial pneumonia (CABP) and urethritis, ... Read more

June 6, 2016June 6, 2016

Pulmonary Arterial Hypertension Candidate by Galectin Shows Positive Results

Pulmonary Hypertension

Galectin Therapeutics, Inc. recently reported that GR-MD-02, the company’s lead candidate galectin-3 (gal-3) inhibitor, has demonstrated a positive effect on vascular remodeling in mouse models of pulmonary arterial hypertension (PAH). The ... Read more

June 5, 2016June 6, 2016

Phase 2 Study of Molecule Inhibitor for Idiopathic Pulmonary Fibrosis Begins

Idiopathic Pulmonary Fibrosis

Kadmon Corporation, which develops first-in-class, innovative therapies against autoimmune and fibrotic diseases, oncology and genetic diseases, recently dosed the first patient in a Phase 2 clinical study of the company’s drug ... Read more

June 1, 2016June 3, 2016

Salford Lung Study Shows Reduction in COPD Exacerbations with Relvar Ellipta

COPD, News

GlaxoSmithKline reported positive results from the pioneering Salford Lung Study (SLS) evaluating Relvar Ellipta 100/25 mcg for the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD). Relvar is ... Read more

May 31, 2016May 31, 2016

‘CF Champions: Navigating the Journey, Together’ Launched by Walgreens

Cystic Fibrosis, News

During The Cystic Fibrosis Foundation’s National CF Awareness Month in May, Walgreens launched “CF Champions: Navigating the Journey, Together,” a campaign to support champion patients and caregivers affected by cystic fibrosis (CF). Cystic ... Read more

May 27, 2016May 27, 2016

Phase 2 Trial for Oral Cystic Fibrosis Treatment Gets Canada’s Green Light

Cystic Fibrosis, News

The Canadian biopharmeceutical corporation ProMetic Life Sciences has been authorized by Health Canada to begin a study on PBI-4050, its orally active anti-fibrotic investigational drug for the treatment of cystic fibrosis (CF). ... Read more

May 26, 2016May 26, 2016

Promising Scleroderma Clinical Trial May Improve Hand Dysfunction

News, Scleroderma

Cytori Therapeutics provided a recent update on results from clinical trials assessing the use of Cytori Cell Therapy (ECCS-50) in the treatment of scleroderma-related hand dysfunction. The presentation was made during the 104th Annual Meeting of the ... Read more

May 24, 2016May 24, 2016

Bayer Ends Phase 2 Trial of Riociguat in PH Patients with Idiopathic Interstitial Pneumonias

News, Pulmonary Hypertension

Bayer has stopped a Phase 2 clinical trial (NCT02138825) evaluating riociguat (Adempas) in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) on the recommendation of the study’s Data Monitoring Committee (DMC). The committee — sometimes ... Read more

May 23, 2016May 23, 2016

Discovered Molecule May Prolong Life of Cystic Fibrosis Patients, Researchers Say

Cystic Fibrosis, News

Scientists at Queen’s University Belfast discovered a new molecule with the potential to prolong the life of individuals with cystic fibrosis (CF). The molecule, QUB-TL1, may be a potential treatment option for ... Read more

May 20, 2016May 20, 2016

Follow-up Data from Study of EBV Treatment in Emphysema Patients Shows Lasting Benefits

Emphysema, News

Pulmonx Corporation reported positive one-year data from the STELVIO trial, the first randomized study evaluating the Zephyr Endobronchial Valve (EBV) in people with severe emphysema, who were selected using the diagnostic Chartis System to identify ... Read more